130 related articles for article (PubMed ID: 37921220)
1. Real-world experience with edoxaban for anticoagulation in children at risk for coronary artery thrombosis.
Sagiv E; Newland DM; Slee A; Olson AK; Portman MA
Cardiol Young; 2024 Apr; 34(4):870-875. PubMed ID: 37921220
[TBL] [Abstract][Full Text] [Related]
2. Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial.
Vranckx P; Valgimigli M; Eckardt L; Lewalter T; Unikas R; Marin F; Schiele F; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Tijssen J; Goette A
Eur Heart J; 2020 Dec; 41(47):4497-4504. PubMed ID: 32860041
[TBL] [Abstract][Full Text] [Related]
3. Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease.
Portman MA; Jacobs JP; Newburger JW; Berger F; Grosso MA; Duggal A; Tao B; Goldenberg NA;
J Am Coll Cardiol; 2022 Dec; 80(24):2301-2310. PubMed ID: 36328157
[TBL] [Abstract][Full Text] [Related]
4. Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48.
Zelniker TA; Ruff CT; Wiviott SD; Blanc JJ; Cappato R; Nordio F; Mercuri MF; Lanz H; Antman EM; Braunwald E; Giugliano RP
Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):176-185. PubMed ID: 30039978
[TBL] [Abstract][Full Text] [Related]
5. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
Qamar A; Antman EM; Ruff CT; Nordio F; Murphy SA; Grip LT; Greenberger NJ; Yin OQP; Choi Y; Lanz HJ; Mercuri MF; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2019 Jul; 74(2):179-189. PubMed ID: 31296289
[TBL] [Abstract][Full Text] [Related]
6. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
Steffel J; Giugliano RP; Braunwald E; Murphy SA; Mercuri M; Choi Y; Aylward P; White H; Zamorano JL; Antman EM; Ruff CT
J Am Coll Cardiol; 2016 Sep; 68(11):1169-1178. PubMed ID: 27609678
[TBL] [Abstract][Full Text] [Related]
7. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
Vranckx P; Valgimigli M; Eckardt L; Tijssen J; Lewalter T; Gargiulo G; Batushkin V; Campo G; Lysak Z; Vakaliuk I; Milewski K; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Goette A
Lancet; 2019 Oct; 394(10206):1335-1343. PubMed ID: 31492505
[TBL] [Abstract][Full Text] [Related]
8. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.
Yin OQ; Tetsuya K; Miller R
Eur J Clin Pharmacol; 2014 Nov; 70(11):1339-51. PubMed ID: 25168620
[TBL] [Abstract][Full Text] [Related]
9. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Mercuri M; Curt V; Betcher J; Grip L; Cange AL; Crompton AE; Murphy SA; Deenadayalu N; Antman EM
J Am Coll Cardiol; 2014 Aug; 64(6):576-84. PubMed ID: 25104527
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
Zelniker TA; Ardissino M; Andreotti F; O'Donoghue ML; Yin O; Park JG; Murphy SA; Ruff CT; Lanz HJ; Antman EM; Braunwald E; Giugliano RP; Merlini PA
Circulation; 2021 Feb; 143(7):673-684. PubMed ID: 33587659
[TBL] [Abstract][Full Text] [Related]
11. Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.
Kuroda M; Tamiya E; Nose T; Ogimoto A; Taura J; Imamura Y; Fukuzawa M; Hayashi T; Akao M; Yamashita T; Lip GYH; Okumura K
JAMA Cardiol; 2022 Jun; 7(6):583-590. PubMed ID: 35416910
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.
Fanola CL; Ruff CT; Murphy SA; Jin J; Duggal A; Babilonia NA; Sritara P; Mercuri MF; Kamphuisen PW; Antman EM; Braunwald E; Giugliano RP
J Am Heart Assoc; 2018 Aug; 7(16):e008987. PubMed ID: 30369307
[TBL] [Abstract][Full Text] [Related]
13. Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy.
Galli M; D'Amario D; Andreotti F; Porto I; Vergallo R; Sabatelli M; Lancellotti S; Meleo E; De Cristofaro R; Crea F
ESC Heart Fail; 2019 Aug; 6(4):884-888. PubMed ID: 31184800
[TBL] [Abstract][Full Text] [Related]
14. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
[TBL] [Abstract][Full Text] [Related]
16. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Van Mieghem NM; Unverdorben M; Hengstenberg C; Möllmann H; Mehran R; López-Otero D; Nombela-Franco L; Moreno R; Nordbeck P; Thiele H; Lang I; Zamorano JL; Shawl F; Yamamoto M; Watanabe Y; Hayashida K; Hambrecht R; Meincke F; Vranckx P; Jin J; Boersma E; Rodés-Cabau J; Ohlmann P; Capranzano P; Kim HS; Pilgrim T; Anderson R; Baber U; Duggal A; Laeis P; Lanz H; Chen C; Valgimigli M; Veltkamp R; Saito S; Dangas GD;
N Engl J Med; 2021 Dec; 385(23):2150-2160. PubMed ID: 34449183
[TBL] [Abstract][Full Text] [Related]
17. Low-Molecular-Weight Heparin vs Warfarin for Thromboprophylaxis in Children With Coronary Artery Aneurysms After Kawasaki Disease: A Pragmatic Registry Trial.
Manlhiot C; Newburger JW; Low T; Dahdah N; Mackie AS; Raghuveer G; Giglia TM; Dallaire F; Mathew M; Runeckles K; Pahl E; Harahsheh AS; Norozi K; de Ferranti SD; Friedman K; Yetman AT; Kutty S; Mondal T; McCrindle BW;
Can J Cardiol; 2020 Oct; 36(10):1598-1607. PubMed ID: 32621885
[TBL] [Abstract][Full Text] [Related]
18. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
[TBL] [Abstract][Full Text] [Related]
19. Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48.
Bonaca MP; Antman EM; Cunningham JW; Wiviott SD; Murphy SA; Halperin JL; Weitz JI; Grosso MA; Lanz HJ; Braunwald E; Giugliano RP; Ruff CT
Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):695-706. PubMed ID: 34962979
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
Vilain K; Li H; Kwong WJ; Antman EM; Ruff CT; Braunwald E; Cohen DJ; Giugliano RP; Magnuson EA;
Circ Cardiovasc Qual Outcomes; 2020 Nov; 13(11):e006511. PubMed ID: 33148013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
